Moderna Korea appoints Ji-Young Sohn as new GM

A marketing specialist with over 20 years of extensive experience…former GM of CSL Behring Korea

“Korea is an important market for Moderna…substantial investment in progress”

Ji-Young Sohn, General Manager of Moderna Korea

Ji-Young Sohn, the former GM of CSL Behring Korea, was appointed as the General Manager of the Korean subsidiary of the COVID-19 vaccine developer Moderna.

 

The new GM will be leading Moderna’s business in Korea and is seeking executives to organize teams that can perform various tasks for the company.

 

The company is currently hiring new executives and employees.

 

Sohn majored in Pharmacy at Ewha University and holds an MBA degree from Korea University Business School.

 

Since then, she has accumulated over 20 years of experience in various global pharmaceutical companies.

 

Before Moderna, the new GM had served as the General Manager of CSL Behring Korea and led the establishment of its Korean subsidiary and the launch of its new products.

 

She started her pharmaceutical career at Pfizer Korea, then expanded her scope of business in the industry at Roche Korea and Roche Headquarters.

 

At Pfizer Korea, Sohn had led various marketing and strategy teams and served as the Head/Director of the company’s first Specialty Care Business Unit.

 

At Roche Korea, she had served as the Head of the Oncology Business Unit, driving strong growth of the oncology business and people development.

 

After then, Sohn moved on to become an international portfolio business leader at Roche Headquarters Switzerland and successfully implemented a global strategy of a mature product portfolio worth 1 trillion won.

 

Patrick Bergstedt, SVP of Commercial Vaccines at Moderna, said, “Sohn is a recognized innovative and strategic leader in Korea and global markets, and we look forward to working with her to reinforce Moderna’s place in Korea.” Sohn said, “Korea is a very important market for Moderna, and Moderna has already made various strategic partnerships and considerable investments in Korea.

 

We will work to build major relations and introduce Moderna’s mRNA science technology to Korea, increase stakeholder trust, and strive to help promote the people's health with Moderna’s excellent vaccines and other future treatments to come."